PALATIN TECHNOLOGIES INC
PTNNASDAQTrading Snapshot
- Day Range
- $4.51 – $5.19
- 52-Week Range
- $4.51 – $31.00
- Volume (shares)
- 42,459
- Avg Volume (shares)
- —
- Shares Outstanding
- 1.8M
- Next Earnings
- 2026-11-11
Fundamentals Snapshot
- Annual Revenue
- $13M
- Last Q Revenue
- $300,770
- P/E Ratio
- -1.0
- P/S Ratio
- 0.7x
- EPS (TTM)
- $-2.14
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +257.0%
PALATIN TECHNOLOGIES INC
PTN
StockOtter · stockotter.spaceAbout PALATIN TECHNOLOGIES INC
Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy. The company also develops PL9643 for dry eye disease and anti-inflammatory ocular indications; and oral PL8177 for the treatment inflammatory bowel diseases. Palatin Technologies, Inc. was incorporated in 1986 and is based in Monmouth Junction, New Jersey.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Analyst Ratings
ⓘLatest News & Updates
What Palatin Technologies (PTN) Said on Its Q4 Earnings Call
Palatin Technologies (NYSEAMERICAN:PTN) said it is prioritizing development of next-generation melanocortin-4 receptor, or MC4R, agonists for rare and syndromic obesity disorders, while also seeking additional financing
Palatin Technologies, Inc. (PTN) Q4 2026 Earnings Call Transcript
Palatin Technologies, Inc. (PTN) Q4 2026 Earnings Call Transcript
Palatin Reports Fiscal Year 2026 Financial Results and Provides Business Update
Palatin Reports Fiscal Year 2026 Financial Results and Provides Business UpdatePR NewswirePRINCETON, N.J., Sept. 28, 2026Programs are focused on rare obesity di
StreetWatch: A $2.9 Billion Takeover Put a Spotlight on Relentless Hunger. Palatin Technologies Is Developing the Next Generation of the Drug That Seeks to Treat It
Rare-endocrine buyers have paid roughly $2.9 billion and approximately $10.0 billion for acquisitions in this area over the past four months. IMCIVREE, the only approved MC4R agonist for acquired hypothalamic obesity and